



CURRICULUM VITAE

SIGNATURE:		DATE:	8/13/2014
NAME:	Ahmad Shah Mohammad, M.D.	DATE	
TITLE:	Principal Investigator	UPDATED:	August 2014

RESEARCH SITE ADDRESS & PHONE:

Main Office: TriWest Research Associates, LLC 300 South Pierce Street, Suite 201 El Cajon, CA 92020	Contact Info: Office: (619) 334-4735 Fax: (619) 334-4769 Email: drmohammad@triwestresearch.com
---	--

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Regensburg, Bavaria, Germany School of Natural Sciences		2008	Movements Disorders and Neurotherapeutics
University of California, San Diego, CA	Fellowship	2008	Movements and Neurotherapeutics
Temple University Hospital, Philadelphia, PA	Residency	2007	Neurology
Temple University Hospital, Philadelphia, PA	Internship	2004	Internal Medicine
Klinikum Nord-Heidberg, Neurosurgery Depart, Hamburg, Germany	Residency	1999	Neurosurgery
University of Hamburg, School of Medicine, Hamburg, Germany	M.D.	1998	Medicine

BOARD CERTIFIED:

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
California Medical License	2007	Neurosurgery

POSITIONS AND EMPLOYMENT:

2013-Present	Principal Investigator, TriWest Research Associates LLC, El Cajon, CA
--------------	---

POSITIONS AND EMPLOYMENT:

2013-Present	Principal Investigator, TriWest Research Associates LLC, El Cajon, CA
2012-Present	Staff Neurologist, Sharp Chula Vista Hospital, Chula Vista, CA
2010-Present	Staff Neurologist, Scripps-Mercy Hospital, Chula Vista, CA
2008-Present	Staff Neurologist, Sharp Grossmont Hospital, La Mesa, CA
2007-2008	Staff Physician, Veterans Affairs Medical Center, San Diego, CA

CLINICAL RESEARCH EXPERIENCE:

Poster presentation in American Epilepsy Society Annual Meeting December 2006 in San Diego:
“Prophylactic antiepileptic therapy in non-traumatic intracerebral hemorrhage”

RJW-333369: A randomized, double-blinded, multicenter, placebo-controlled, Phase II trial of XXXX as a new adjunctive therapy for partial seizure”

Allergan 191622-516: A randomized, double-blinded, multi-centric, placebo-controlled, Phase II trial of Botox (Botulinum Toxin type A) for Spastic Bladder in Multiple Sclerosis patients

Cohort: Comprehensive Huntington Disease Research Trial: A multi-centric longitudinal follow-up study of Huntington patients and their family members

Endo Pharmaceuticals, Inc., “A Phase IIB, Randomized, Double-Blind, Two-Arm, Multi-Center, Placebo-Controlled, Study to Assess the Efficacy and Safety of XXXX in Subjects with Moderate to Severe Chronic Low Back Pain.”

Abbott Laboratories. “A Global Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of XXXX to Placebo in Subjects with Osteoarthritis Pain of the Knee.

Pfizer Pharmaceuticals XXXX. A Phase III. Multi-Center, Randomized, Double blind, Controlled study of the long term analgesic efficacy of XXXX alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) versus NSAIDs alone in patients with Osteoarthritis of the knee or hip.

Ferring Pharmaceuticals. XXXX. A Phase II, 26 week, Double blind, Randomized, Placebo controlled trial of the efficacy and safety of single Intra-Articular injection 1.2% sodium Hyaluronate for treatment of painful Osteoarthritis of the knee, with optional 26 week open-label extension.

Regeneron Pharmaceuticals. XXXX. A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel-Group Study of the safety and efficacy of subcutaneously administered XXXX in patients with Sciatic Pain.